文献速递母胎医学产科

先天性肝内门体分流:胎儿生长受限合并羊水过少的代偿机制

Intrahepatic portosystemic shunt: salvage mechanism for oligohydramnios complicating fetal growth restriction.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-01-21

该回顾性研究纳入2018年1月至2022年12月间2144例疑似胎儿生长受限的单胎妊娠,其中12例初诊时羊水过少、后续诊断先天性肝内门体分流(CIPSS)。诊断CIPSS后羊水指数中位数从5 cm显著改善至13 cm(P=0.002),f-TAPSE从4.0 mm显著增至8.0 mm(P=0.043),所有新生儿分流在30个月内自发消退。

要点

  • 生长受限胎儿合并羊水过少时,随访中出现CIPSS提示分流代偿现象。
  • 诊断CIPSS后羊水指数中位数由5 cm升至13 cm,f-TAPSE由4.0 mm升至8.0 mm。
  • 75%(9/12)分流位于左门静脉至左肝静脉,所有新生儿分流在30个月内自发消退。

核心结论

  • 生长受限胎儿合并羊水过少时出现CIPSS似乎可改善血流动力学状态,表现为羊水指数正常化和f-TAPSE增加。

研究设计与样本

  • 回顾性研究,纳入2018年1月至2022年12月间一家大型三级转诊中心的2144例疑似胎儿生长受限的单胎妊娠,其中12例初诊时羊水过少并在随访中诊断CIPSS。
  • 常规评估包括估测胎儿体重、生物物理评分、多普勒成像、脐-门静脉系统全面检查及胎儿三尖瓣环收缩期位移(f-TAPSE)评估心功能。
  • 采用描述性统计和Wilcoxon符号秩检验比较羊水过少缓解前后的参数。

主要发现

  • 诊断生长受限和羊水过少的中位孕周为25周(范围21-30周),10/12胎儿估测体重位于第1百分位。
  • 羊水指数中位数从初诊时5 cm(范围2-5 cm)显著改善至分流诊断后13 cm(范围11-20 cm)(P=0.002)。
  • 有f-TAPSE数据的胎儿中,f-TAPSE从CIPSS诊断前4.0 mm(范围3.0-5.0 mm)显著增至诊断后8.0 mm(范围5.0-9.4 mm)(P=0.043)。
  • 分娩中位孕周为36.3周(范围30.8-38.4周),9例(75%)分流为左门静脉至左肝静脉。
  • 所有新生儿随访显示分流在30个月内自发消退,1例新生儿因疑似分流接受栓塞术但术中未检测到分流。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Portosystemic shunts in growth-restricted fetuses are more common than previously thought. We aimed to describe fetuses with growth restriction and transient oligohydramnios in which a congenital intrahepatic portosystemic shunt (CIPSS) was noted during follow-up. METHODS: This was a retrospective study of all fetuses diagnosed with growth restriction and transient oligohydramnios during a 5-year period in a large tertiary referral center. Our routine evaluation of growth-restricted fetuses includes monitoring of estimated fetal weight, assessment of biophysical profile, Doppler imaging, thorough examination of the umbilical-portal system and evaluation of cardiac function using fetal tricuspid annular plane systolic excursion (f-TAPSE). We compared these parameters before and after the resolution of the oligohydramnios using descriptive statistics and the Wilcoxon signed-rank test for paired non-parametric variables. During the surveillance of fetuses with transient oligohydramnios, we noted the appearance of a CIPSS and followed up such cases after birth. RESULTS: A total of 2144 women with a singleton pregnancy with suspected fetal growth restriction were referred to our center between January 2018 and December 2022. In 12 fetuses, oligohydramnios was evident upon initial assessment, and a CIPSS was diagnosed with normalization of amniotic fluid level. The median gestational age at diagnosis of growth restriction and oligohydramnios was 25 (range, 21-30) weeks. The estimated fetal weight was at the 1st percentile in 10/12 fetuses. The median amniotic fluid index was 5 (range, 2-5) cm at the initial appointment and improved significantly to 13 (range, 11-20) cm following the shunt diagnosis (P = 0.002). Among fetuses with f-TAPSE data available, the f-TAPSE increased significantly from 4.0 (range, 3.0-5.0) mm before the diagnosis of CIPSS to 8.0 (range, 5.0-9.4) mm following the diagnosis (P = 0.043). The median gestational age at delivery was 36.3 (range, 30.8-38.4) weeks. In nine (75%) fetuses, the diagnosed shunt was left portal to left hepatic vein. Neonatal follow-up revealed spontaneous shunt resolution within 30 months in all newborns. One newborn required embolization owing to suspected shunt, however, no shunt was detected during the procedure. CONCLUSIONS: The development of CIPSS in growth-restricted fetuses with oligohydramnios appears to improve hemodynamic status as evidenced by normalization of amniotic fluid index and increase in f-TAPSE. Evaluation of the liver portal system in fetuses with growth restriction offers an understanding of the shunt salvage phenomenon. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gilboa Y, Drukker L, Bar J, et al. Intrahepatic portosystemic shunt: salvage mechanism for oligohydramnios complicating fetal growth restriction. Ultrasound Obstet Gynecol. 2025. PMID: 39836071. doi:10.1002/uog.29163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。